Revenue
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Rein Therapeutics, Inc. (RNTX)
Price$0.8891Cached quote
Net income
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2017
2018
2019
2020
2021
Total cash / debt
CashTotal debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $11.0M | $14.2M | $4.0M | $18.0M | $17.0M | $11.2M | $17.7M | $18.4M | $14.2M | $10.3M | $7.8M |
| Operating expenses | $50.6M | $65.1M | $16.3M | $27.6M | $26.6M | $20.5M | $30.0M | $31.9M | $23.0M | $18.2M | $12.9M |
| Operating income | −$50.6M | −$65.1M | −$16.3M | −$27.6M | −$26.6M | −$20.5M | −$30.0M | −$31.9M | −$23.0M | −$18.2M | −$12.9M |
| EBITDA | −$50.6M | −$65.0M | −$16.2M | −$27.5M | −$26.5M | −$20.3M | −$29.8M | −$31.7M | −$22.9M | −$17.9M | −$12.6M |
| Net income | −$49.9M | −$62.9M | −$15.7M | −$27.3M | −$26.2M | −$27.3M | −$29.4M | −$31.5M | −$22.6M | −$18.1M | −$12.9M |
| Basic EPSper basic share | -$1.96 | -$3.51 | -$3.42 | -$6.02 | -$5.89 | -$12.20 | -$24.00 | -$42.80 | -$60.80 | -$847.00 | -$646.20 |
| Diluted EPSper diluted share | -$1.96 | -$3.51 | -$3.42 | -$6.02 | -$5.89 | -$12.20 | -$24.00 | -$42.80 | -$60.80 | -$847.00 | -$646.20 |
Owners
Reported shareholders
6.14%of listed shares
Voss Capital, LP5.26M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Voss Capital, LP | 6.14%5.26M shares |
Cable Car Capital, LP | 6.06%5.2M shares |
ADAR1 Capital Management, LLC | 5.25%4.5M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.94%3.38M shares |
BIOS Capital Management, LP | 3.48%2.98M shares |
Ikarian Capital, LLC | 3.44%2.95M shares |
GREAT POINT PARTNERS LLC | 3.00%2.58M shares |
CITADEL ADVISORS LLC | 2.84%2.44M shares |
Velan Capital Investment Management LP | 1.98%1.7M shares |
Senvest Management, LLC | 1.44%1.23M shares |
Prosight Management, LP | 1.28%1.1M shares |
Bleichroeder LP | 1.17%1M shares |
BOOTHBAY FUND MANAGEMENT, LLC | 1.04%889.45K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.85%733.14K shares |
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 0.60%511.61K shares |
VANGUARD FIDUCIARY TRUST CO | 0.45%382.52K shares |
STATE STREET CORP | 0.44%379.6K shares |
Empery Asset Management, LP | 0.43%370.83K shares |
Sigma Planning Corp | 0.41%353.68K shares |
BlackRock, Inc. | 0.38%326.2K shares |
Percentages use 85.77M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 27, 2026Form 4 | VON RICKENBACH JOSEF HDirector | BuyCommon stock , $0.001 par value | 4.5K | $1.07 | $4.8K | 62.5K |
| May 26, 2026Form 4 | VON RICKENBACH JOSEF HDirector | BuyCommon stock , $0.001 par value | 23.2K | $1.06 | $24.6K | 58.0K |
| May 22, 2026Form 4 | VON RICKENBACH JOSEF HDirector | BuyCommon stock , $0.001 par value | 15.9K | $1.05 | $16.7K | 34.8K |
| May 21, 2026Form 4 | VON RICKENBACH JOSEF HDirector | BuyCommon stock , $0.001 par value | 3.4K | $1.04 | $3.6K | 18.9K |
| Apr 30, 2026Form 4 | WINDSOR JAMES BRIANSee Remarks | BuyCommon stock , $0.001 par value | 25.0K | $1.00 | $25.0K | 27.0K |